Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners. The group is a member of K.G. Jebsen Center for Cancer Immunotherapy (Center Director: Olweus).
Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton
J Cell Sci (in press)
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nat Commun, 12 (1), 5172
Chromothripsis as a pathogenic driver of multiple myeloma
Semin Cell Dev Biol (in press)